Research & Literature

Targeted therapies in advanced differentiated thyroid cancer.

Carneiro RM, Carneiro BA, Agulnik M, et al.

Cancer treatment reviews 2015; (41(8)):690-8.

Current Guidelines for Postoperative Treatment and Follow-Up of Well-Differentiated Thyroid Cancer.

Yoo JY, Stang MT

Surgical oncology clinics of North America 2016; (25(1)):41-59.

Differentiated thyroid cancer: feasibility of loboisthmectomy in an endemic region.

Calò G, Erdas E, Medas F, et al.

Il Giornale di chirurgia 2015; (36(6)):257-62 doi:10.11138/gchir/2015.36.6.257.

Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine.

Momesso DP, Vaisman F, Yang SP, et al.

The Journal of clinical endocrinology and metabolism 2016; (101(7)):2692-700 doi:10.1210/jc.2015-4290.

Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: A name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment.

Thompson LD

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016; (29(7)):698-707 doi:10.1038/modpathol.2016.65.

A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma.

Vuong HG, Duong UN, Altibi AM, et al.

Endocrine connections 2017; (6(3)):R8-R17 doi:10.1530/EC-17-0010.

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.

Lim H, Devesa SS, Sosa JA, et al.

JAMA 2017; (317(13)):1338-1348 doi:10.1001/jama.2017.2719.

Dynamic risk stratification in the follow-up of thyroid cancer: what is still to be discovered in 2017?

Krajewska J, Chmielik E, Jarząb B

Endocrine-related cancer 2017; (24(11)):R387-R402 doi:10.1530/ERC-17-0270.

The Hobnail Variant of Papillary Thyroid Carcinoma: Clinical/Molecular Characteristics of a Large Monocentric Series and Comparison with Conventional Histotypes.

Watutantrige-Fernando S, Vianello F, Barollo S, et al.

Thyroid : official journal of the American Thyroid Association 2018; (28(1)):96-103 doi:10.1089/thy.2017.0248.

The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7.

Verburg FA, Mäder U, Luster M, Reiners C

Clinical endocrinology 2018; (88(6)):950-956 doi:10.1111/cen.13597.

Health-Related Quality of Life of Community Thyroid Cancer Survivors in Hangzhou, China.

Wang T, Jiang M, Ren Y, et al.

Thyroid : official journal of the American Thyroid Association 2018; (28(8)):1013-1023 doi:10.1089/thy.2017.0213.

Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer.

van Velsen EFS, Stegenga MT, van Kemenade FJ, et al.

Thyroid : official journal of the American Thyroid Association 2018; (28(8)):976-981 doi:10.1089/thy.2018.0066.

Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma.

Janovitz T, Barletta JA

Endocrine pathology 2018; (29(4)):357-364 doi:10.1007/s12022-018-9548-1.

Usefulness of dynamic risk stratification in pediatric patients with differentiated thyroid carcinoma.

Kim K, Kim WW, Choi JB, et al.

Annals of surgical treatment and research 2018; (95(4)):222-229 doi:10.4174/astr.2018.95.4.222.

Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.

Oh HS, Ahn JH, Song E, et al.

Thyroid : official journal of the American Thyroid Association 2019; (29(2)):209-215 doi:10.1089/thy.2018.0391.

Thyroid tumors with follicular architecture.

Turk AT, Wenig BM

Annals of diagnostic pathology 2019; (38()):51-58 doi:10.1016/j.anndiagpath.2018.10.007.

Genetic-guided Risk Assessment and Management of Thyroid Cancer.

Xing M

Endocrinology and metabolism clinics of North America 2019; (48(1)):109-124 doi:10.1016/j.ecl.2018.11.007.

Conservative Surveillance Management of Low-Risk Papillary Thyroid Microcarcinoma.

Miyauchi A, Ito Y

Endocrinology and metabolism clinics of North America 2019; (48(1)):215-226 doi:10.1016/j.ecl.2018.10.007.

Evolving Understanding of the Epidemiology of Thyroid Cancer.

Seib CD, Sosa JA

Endocrinology and metabolism clinics of North America 2019; (48(1)):23-35 doi:10.1016/j.ecl.2018.10.002.

Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features is Rare: A Population Based Study of Incidence.

Reinke RH, Larsen SR, Mathiesen JS, et al.

Head and neck pathology 2020; (14(1)):144-149 doi:10.1007/s12105-019-01032-2.

THYROGLOBULIN AS A TUMOR MARKER IN DIFFERENTIATED THYROID CANCER - CLINICAL CONSIDERATIONS.

Prpić M, Franceschi M, Romić M, et al.

Acta clinica Croatica 2018; (57(3)):518-527 doi:10.20471/acc.2018.57.03.16.

SIZE OF THE LARGEST METASTATIC FOCUS TO THE LYMPH NODE IS ASSOCIATED WITH INCOMPLETE RESPONSE OF PN1 PAPILLARY THYROID CARCINOMA.

Deng Y, Zhu G, Ouyang W, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(9)):887-898 doi:10.4158/EP-2018-0583.

Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?

Harries V, Wang LY, McGill M, et al.

Surgery 2020; (167(1)):10-17 doi:10.1016/j.surg.2019.03.031.

Prognostic Parameters in Differentiated Thyroid Carcinomas.

Cipriani NA

Surgical pathology clinics 2019; (12(4)):883-900 doi:10.1016/j.path.2019.07.001.

Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.

Trimboli P, Piccardo A, Signore A, et al.

Thyroid : official journal of the American Thyroid Association 2020; (30(5)):713-719 doi:10.1089/thy.2019.0688.

Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis.

Lan X, Bao H, Ge X, et al.

Cancer science 2020; (111(6)):2163-2173 doi:10.1111/cas.14389.

Follow-up of low risk thyroid cancer patients: can we stop follow-up after 5 years of complete remission?

Lamartina L, Handkiewicz-Junak D

European journal of endocrinology 2020; (182(5)):D1-D16.

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.

Al-Salam S, Sharma C, Afandi B, et al.

PloS one 2020; (15(4)):e0231341 doi:10.1371/journal.pone.0231341.

Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system.

Kim K, Kim JK, Lee CR, et al.

Therapeutic advances in endocrinology and metabolism 2020; (11()):2042018820921019 doi:10.1177/2042018820921019.

New paradigms in the treatment of low-risk thyroid cancer.

Baidoun F, Saad AM, Abdel-Rahman O

Expert review of endocrinology & metabolism 2020; (15(4)):251-260 doi:10.1080/17446651.2020.1773802.

Current practice in patients with differentiated thyroid cancer.

Schlumberger M, Leboulleux S

Nature reviews. Endocrinology 2021; (17(3)):176-188 doi:10.1038/s41574-020-00448-z.

[Diagnostic principles of thyroid tumors in pathology : Relevant changes due to the current WHO classification].

Theurer S, Rawitzer J, Ting S, Schmid KW

Der Pathologe 2021; (42(1)):125-139 doi:10.1007/s00292-020-00908-3.

The Prognostic Role of Postablative Non-Stimulated Thyroglobulin in Differentiated Thyroid Cancer.

Szujo S, Bajnok L, Bodis B, et al.

Cancers 2021; (13(2)) doi:10.3390/cancers13020310.

Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.

Soares P, Póvoa AA, Melo M, et al.

Endocrine pathology 2021; (32(1)):44-62 doi:10.1007/s12022-021-09666-1.

Optimal Timing of Initiating Dynamic Risk Stratification During the Early Postoperative Period in Patients with Differentiated Thyroid Carcinoma After Thyroidectomy and Radioactive Iodine Remnant Ablation.

Park JH, Moon GS, Nam KT, Yoon JH

Annals of surgical oncology 2021; (28(11)):6580-6589 doi:10.1245/s10434-021-09721-5.

Redifferentiation-facilitated radioiodine therapy in thyroid cancer.

Lamartina L, Anizan N, Dupuy C, et al.

Endocrine-related cancer 2021; (28(10)):T179-T191.

How Does The AJCC/TNM Staging System Eighth Edition Perform in Thyroid Cancer at A Major Middle Eastern Medical Center?

Alzahrani AS, Albalawi L, Mazi S, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2021; (27(6)):607-613 doi:10.1016/j.eprac.2020.11.018.

Health-Related Quality of Life in Asian Differentiated Thyroid Cancer Survivors.

Chan WL, Choi HC, Lang B, et al.

Cancer control : journal of the Moffitt Cancer Center 2021; (28()):10732748211029726 doi:10.1177/10732748211029726.

Differentiated Thyroid Cancer in Children and Adolescents: Long Term Outcome and Risk Factors for Persistent Disease.

Sapuppo G, Hartl D, Fresneau B, et al.

Cancers 2021; (13(15)) doi:10.3390/cancers13153732.

Long-Term Prognostic Value of the Response to Therapy Assessed by Laboratory and Imaging Findings in Patients with Differentiated Thyroid Cancer.

Klain M, Zampella E, Piscopo L, et al.

Cancers 2021; (13(17)) doi:10.3390/cancers13174338.

Incidence and mortality trends of thyroid cancer from 1980 to 2016.

Wirth S, Syleouni ME, Karavasiloglou N, et al.

Swiss medical weekly 2021; (151()):w30029.

Differentiated Thyroid Cancer with Biochemical Incomplete Response: Clinico-Pathological Characteristics and Long Term Disease Outcomes.

Steinschneider M, Pitaro J, Koren S, et al.

Cancers 2021; (13(21)) doi:10.3390/cancers13215422.

A New Dynamic Response to Therapy Assessment in Postoperative Patients With Low-Risk Differentiated Thyroid Cancer Treated Without Radioactive Iodine.

Dong P, Wang L, Xiao L, et al.

Frontiers in oncology 2021; (11()):764258 doi:10.3389/fonc.2021.764258.

Active surveillance of low-risk papillary thyroid microcarcinoma.

Sugitani I

Best practice & research. Clinical endocrinology & metabolism 2023; (37(1)):101630 doi:10.1016/j.beem.2022.101630.

Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.

Kim M, Jin M, Jeon MJ, et al.

Thyroid : official journal of the American Thyroid Association 2023; (33(1)):91-99 doi:10.1089/thy.2022.0054.

Active surveillance is an excellent management technique for identifying patients with progressive low-risk papillary thyroid microcarcinoma requiring surgical treatment.

Fujishima M, Miyauchi A, Ito Y, et al.

Endocrine journal 2023; (70(4)):411-418 doi:10.1507/endocrj.EJ22-0559.

The Impact of the 2022 WHO Classification of Thyroid Neoplasms on Everyday Practice of Cytopathology.

Rossi ED, Baloch Z

Endocrine pathology 2023; (34(1)):23-33 doi:10.1007/s12022-023-09756-2.

Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.

Zhang L, Li Z, Zhang M, et al.

Medical oncology (Northwood, London, England) 2023; (40(9)):258 doi:10.1007/s12032-023-02098-3.

Mortality rate and causes of death in papillary thyroid microcarcinoma.

Heo J, Ryu HJ, Park H, et al.

Endocrine 2024; (83(3)):671-680 doi:10.1007/s12020-023-03510-8.

Risk Stratification of Differentiated Thyroid Cancer: A Single-Center Study in Basrah.

Jasim MS, Hussein IH, Alidrisi HA, Mansour AA

Cureus 2023; (15(10)):e47990 doi:10.7759/cureus.47990.

Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update.

Bischoff LA, Ganly I, Fugazzola L, et al.

JAMA otolaryngology-- head & neck surgery 2024; (150(3)):265-272 doi:10.1001/jamaoto.2023.4323.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.

Yu J, Liu Z, Su Y, et al.

Clinical endocrinology 2024; (100(4)):379-388 doi:10.1111/cen.15027.

Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review.

Hampton J, Alam A, Zdenkowski N, et al.

Thyroid : official journal of the American Thyroid Association 2024; (34(5)):541-558 doi:10.1089/thy.2023.0642.

WHO 2022 updates on follicular cell and c-cell derived thyroid neoplasm.

Goswami P, Patel T, Dave R, et al.

Journal of medicine and life 2024; (17(1)):15-23 doi:10.25122/jml-2023-0270.

Application value of multi-gene mutation detection in the clinical management of pediatric papillary thyroid carcinoma: a preliminary exploration.

Wang Y, Wang H, Tan G, et al.

Frontiers in endocrinology 2024; (15()):1405142 doi:10.3389/fendo.2024.1405142.

Environmental factors related to the origin and evolution of differentiated thyroid cancer: a narrative review.

Paz-Ibarra J, Concepción-Zavaleta MJ, Quiroz-Aldave JE

Expert review of endocrinology & metabolism 2024; (19(6)):469-477 doi:10.1080/17446651.2024.2377687.

Data-driven Thyroglobulin Cutoffs for Low- and Intermediate-risk Thyroid Cancer Follow-up: ITCO Real-world Analysis.

Grani G, D'Elia S, Puxeddu E, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(5)):e1377-e1384 doi:10.1210/clinem/dgae559.

Radioactive iodine ablation therapy reduces the risk of recurrent disease in pediatric differentiated thyroid carcinoma.

Toraih E, Webster A, Pineda E, et al.

Surgical oncology 2024; (56()):102120 doi:10.1016/j.suronc.2024.102120.

Dose-dependent relationship between levothyroxine and health-related quality of life in survivors of differentiated thyroid cancer.

Braafladt S, Allison H, Chung J, et al.

Surgery 2025; (179()):108799 doi:10.1016/j.surg.2024.07.057.

Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

Effects of a mobile health intervention based on a multitheoretical model of health behavior change on anxiety and depression, fear of cancer progression, and quality of life in patients with differentiated thyroid cancer: A randomized controlled trial.

Sun X, Jiang Y, Wang J, et al.

BMC medicine 2024; (22(1)):466 doi:10.1186/s12916-024-03652-0.

Contribution of neck ultrasonography to patient management in patients with differentiated thyroid carcinoma with excellent response to therapy.

Hekimsoy İ, Güven M, Tokaç RH, et al.

Endocrine 2025; (88(1)):135-142 doi:10.1007/s12020-024-04147-x.

Examining the Sequential Relationships Between Voice Changes, Symptom Experiences, Fear of Cancer Recurrence, and Voice-Related Quality of Life in Patients With Thyroid Cancer: A Cross-sectional Study.

Lee MK, Oh J

Cancer nursing 2025; doi:10.1097/NCC.0000000000001466.

Impact of microscopic margin involvement on recurrence of papillary thyroid carcinoma.

Kwon H, Kim H, Hwang H, Moon BI

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2025; (51(9)):110208 doi:10.1016/j.ejso.2025.110208.

The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline.

Moon S, Song YS, Jung KY, et al.

Endocrinology and metabolism (Seoul, Korea) 2025; (40(3)):357-384 doi:10.3803/EnM.2025.2465.

Pure red-cell aplasia after radioactive iodine treatment in a patient with papillary thyroid cancer and follow up for two years: a case report.

Li R, Wang M, Li S, Liao L

Frontiers in oncology 2025; (15()):1539586 doi:10.3389/fonc.2025.1539586.

Survivorship and Quality of Life in Thyroid Cancer Survivors.

McCabe JK, Keller HR, Goldfarb M

Endocrinology and metabolism clinics of North America 2025; (54(3)):469-481 doi:10.1016/j.ecl.2025.03.015.

Alone with the diagnosis: A reflective analysis on imaging report access and emotional burden.

Chau M

Radiography (London, England : 1995) 2025; (31 Suppl 2()):103104 doi:10.1016/j.radi.2025.103104.

Long-Term Outcomes of Patients Diagnosed With Differentiated Thyroid Cancer in Childhood and Young Adulthood.

Valenciaga A, Liyanarachchi S, Brock PL, Ringel MD

The Journal of clinical endocrinology and metabolism 2026; (111(3)):e715-e724 doi:10.1210/clinem/dgaf522.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

"You Always Worry": Scan-Related Anxiety Among Patients With Metastatic Lung Cancer.

Derry-Vick H, Prigerson HG, Hahne J, et al.

Journal of the American College of Radiology : JACR 2025; (22(12)):1572-1577 doi:10.1016/j.jacr.2025.08.021.

Psychological impacts of thyroid cancer diagnosis and treatment-a retrospective study.

Liu X, Shi J, Gu H, Wang X

Frontiers in psychology 2025; (16()):1697978 doi:10.3389/fpsyg.2025.1697978.

Prognostic Value of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis of Nodal Involvement, Distant Metastases, Recurrence, and Mortality.

Gatta E, Pirola I, Gandossi E, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(3)):416-426 doi:10.1016/j.eprac.2025.12.003.

SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.

Ruz-Caracuel I, Alonso-Gordoa T, Hernández S, et al.

Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia 2026; (59(2)):100859 doi:10.1016/j.patol.2026.100859.